These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12022190)

  • 1. FDA's implementation of FDAMA: an interim balance sheet.
    Suydam LA; Kubic MJ
    Food Drug Law J; 2001; 56(2):131-5. PubMed ID: 12022190
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA's FDAMA accomplishments--one year after enactment.
    Ann Pharmacother; 1999 Jan; 33(1):134. PubMed ID: 9972401
    [No Abstract]   [Full Text] [Related]  

  • 3. FDAMA update.
    Suydam LA; Elder DK
    Food Drug Law J; 1999; 54(1):21-33. PubMed ID: 11758557
    [No Abstract]   [Full Text] [Related]  

  • 4. Protecting FDA's ability to protect public health.
    Taylor MR
    Food Drug Law J; 2006; 61(4):805-8. PubMed ID: 17180774
    [No Abstract]   [Full Text] [Related]  

  • 5. Advisory committees" critical to the FDA's product review process.
    Rados C
    FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA's new drug rating system.
    Ohio Med; 1991 Mar; 87(3):133-4. PubMed ID: 2030884
    [No Abstract]   [Full Text] [Related]  

  • 7. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ECRI comments on FDA's reuse plan.
    Healthc Hazard Manage Monit; 2000 Jun; 13(10):4-5. PubMed ID: 11125912
    [No Abstract]   [Full Text] [Related]  

  • 9. No dillydallying: Barton. Proposed legislation in response to GAO report on FDA's slow debarment.
    Rhea S
    Mod Healthc; 2009 Oct; 39(43):12-3. PubMed ID: 19972653
    [No Abstract]   [Full Text] [Related]  

  • 10. Women's health advocates dismayed at FDA's Plan B decision.
    Ready T
    Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA's decision on Plan B: a surrogate for lack of commitment to women's health.
    Merkatz RB
    J Womens Health (Larchmt); 2005 Nov; 14(9):860. PubMed ID: 16313214
    [No Abstract]   [Full Text] [Related]  

  • 12. DSHEA provisions confine FDA's authority to issue regulations that concern allegedly adulterated dietary supplements.
    McNamara SH; Siegner AW; Phelps EP
    Food Drug Law J; 1999; 54(4):595-8. PubMed ID: 11824456
    [No Abstract]   [Full Text] [Related]  

  • 13. FDA's emergency research rule: an inch given, a yard taken.
    Gillenwater GE
    Food Drug Law J; 2008; 63(1):217-56. PubMed ID: 18561460
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA's perspective on clinical laboratory devices. The premarket review and evaluation process.
    Aziz KJ; Sliva CA; Gutman SI
    Am Clin Lab; 1996; 15(1):10-1. PubMed ID: 10163487
    [No Abstract]   [Full Text] [Related]  

  • 15. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 16. Food industry initiatives to improve the FDA's food ingredient review processes.
    Pape SM
    Food Drug Law J; 1996; 51(3):413-21. PubMed ID: 11797718
    [No Abstract]   [Full Text] [Related]  

  • 17. An overview of FDA medical device regulation as it relates to deep brain stimulation devices.
    Peña C; Bowsher K; Costello A; De Luca R; Doll S; Li K; Schroeder M; Stevens T
    IEEE Trans Neural Syst Rehabil Eng; 2007 Sep; 15(3):421-4. PubMed ID: 17894274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Petition to request an exemption from 100 percent identity testing of dietary ingredients: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements. Interim final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2007 Jun; 72(121):34959-69. PubMed ID: 17674485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remarks of the Commissioner of Food and Drugs.
    Henney JE
    Food Drug Law J; 1999; 54(1):1-3. PubMed ID: 11794304
    [No Abstract]   [Full Text] [Related]  

  • 20. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.